PODD · 10-Q · 2026Q2 · Full report
Omnipod Product Development
INSULET CORP · 2026-08-05 · Importance 31 · Surprise 42 · In source text
Insulet increased research and development investment to support its Omnipod platform and pipeline products. Development priorities include Omnipod 6, described as the next-generation automated insulin delivery system, and a fully closed-loop automated insulin delivery system for people with type 2 diabetes. These initiatives are intended to expand the company’s technology offering beyond current Omnipod products and support future product growth.
Key facts
- The Company is currently developing Omnipod 6, its next generation AID product, and advanced development of a fully closed-loop AID system for people with type 2 diabetes, including enrolling the first participant in the EVOLVE pivotal study to support a planned 510(k) submission in 2027. source
- Omnipod 5 expanded compatibility with Abbott’s Freestyle Libre 3 Plus sensor in the United States in June 2026 and the U.S. rollout of Omnipod 5 algorithm enhancements including a lower 100 mg/dL target glucose set point was announced in June 2026. source
- The increase in research and development expenses in both the three and six months ended June 30, 2026 were primarily due to continued investment in our Omnipod and pipeline products, including Omnipod 6, our next generation AID system, and a fully closed-loop AID system for type 2 diabetes. source
Impact estimates
| metric | direction | stage | expected | basis |
|---|---|---|---|---|
| operating_income | negative | probable | — | The Company is currently developing Omnipod 6, its next generation AID product, and advanced development of a fully closed-loop AID system… |
| revenue | positive | probable | — | Omnipod 5 expanded compatibility with Abbott’s Freestyle Libre 3 Plus sensor in the United States in June 2026 and the U.S. rollout of… |